Atara Q3 net loss narrows to $21.9M; tab-cel PDUFA Jan 15, 2025; CLO departs

Atara Biotherapeutics, Inc.

2024-Q3 EPS reported -$11.34 revenue$96,187,000

Net loss $21.9M ($2.93/share) vs $69.8M ($16.40) YoY; revenue rose to $40.2M from $2.1M.
Cash, equivalents & investments $67.2M; net cash used in ops $4.0M vs $51.3M; cash runway into 2027.
Tab-cel BLA on track; PDUFA Jan 15, 2025; no advisory committee; potential $60M milestone from Pierre Fabre.
First patient dosed in ATA3219 NHL study; initial data Q1 2025. Lupus nephritis study start by year-end; data mid-2025.
Chief Legal Officer Amar Murugan departed Nov 8; consulting role at $250/hr; severance and bonuses tied to tab-cel milestones.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Amar Murugan

Chief Legal Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2024-11-08
Filed: November 12, 2024, 6:59 PM ET

On November 8, 2024, it was agreed that the employment of Amar Murugan, the Company’s Chief Legal Officer, would end effective November 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amar Murugan departed as Chief Legal Officer at Atara Biotherapeutics, Inc..

Action: departed
Role: Chief Legal Officer

Exact text from the filing

On November 8, 2024, it was agreed that the employment of Amar Murugan, the Company’s Chief Legal Officer, would end effective November 8, 2024.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-125334

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.